Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of multiple doses of
CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current
therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total
triglycerides and chylomicron triglyceride levels in patients with severe
hypertriglyceridemia.
This is a single-blind study. All patients will receive placebo for a 14 day treatment period
and CAT-2003 for a 28 day treatment period.